India's indigenous vaccine Covaxin from Bharat Biotech cleared for phase III trials

▴ India's indigenous vaccine Covaxin from Bharat Biotech cleared for phase III trials
Bharat Biotech's Covaxin could be the first vaccine to hit the market

In a huge boost to India's indigenous vaccine plan, Bharat Biotech has been given clearance for phase three trials in India. Covaxin's third phase trials will start in the first week of November.

Under the Phase 3 trial, the vaccine will be administered to 22 thousand people across 19 places. The government aims to vaccinate 20 to 25 crore people between January and July next year.

The government has also sought a list of all those who will be given the vaccine. Initially, the vaccine will be given on a priority basis. It is to be noted that India manufacturers around 60% of vaccine supply worldwide.

The focused efforts of Centre and State/UT governments on effective clinical management of the hospitalized cases have ensured that India’s Fatality Rate has touched 1.5%. Less than 500 deaths (480) have been reported in the last 24 hours in the country. India has one of the lowest fatality rates in the world. The Case Fatality rate is lowest since 22nd March and is continuously declining. 2218 Dedicated COVID Hospitals are providing quality medical care. At the ground level, frontline health workers like ASHAs and ANMs have done a commendable job of managing the migrant population and to enhance awareness at the community level.

As a result, there are 14 States and UTs with CFR lower than 1%.59,105 new recoveries were added in the last 24 hour whereas new recovered cases were 45,148. With this, the total number of recoveries have crossed 71 Lakh (71,37,228). A higher number of single-day recoveries is also reflected in the continuous increase in the national recovery rate, which is at present 90.23%. India continues to report a trend of steadily decreasing active cases.

Presently the active cases comprise merely 8.26% of the total positive cases of the country standing at 6,53,717. This is the lowest since 13th August when the active cases were 6,53,622. 78% of the new recovered cases are observed to be concentrated in 10 States/UTs. Karnataka has contributed the maximum to the single-day recoveries with more than 10,000 cases followed by Kerala with more than 7,000 cases. 45,148 new confirmed cases were registered in the last 24 hours in the country.

This is the lowest since 22nd July when 37,000 new cases were added. 82% of new confirmed cases are from 10 States and UTs. Kerala and Maharashtra contribute maximum to the new confirmed cases with more than 6,000 cases each followed by Karnataka, Delhi and West Bengal with more than 4,000 cases. 480 case fatalities have been reported in the past 24 hours. Of these, nearly 80% are concentrated in ten States/UTs. More than 23% of new fatalities reported are from Maharashtra (112 deaths).

Tags : #Covaxin #BharatBiotech #CovidVaccineNewsOct27 #IndiaCovidNewsOct27 #IndiaCaseFatalityRateOct27

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Covid technical Advisory panel advises Karnataka health dept to be prepared for 2nd wave of COVID-19 pandemicDecember 04, 2020
Telangana reports 631 fresh cases of COVID-19December 04, 2020
Odisha crosses milestone in conducting over 6 million tests for COVID-19December 04, 2020
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary EndpointDecember 04, 2020
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene TherapyDecember 04, 2020
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal EncephalopathyDecember 04, 2020
I2O Therapeutics receives strategic investment from Colorcon VenturesDecember 04, 2020
Study shows personalized provider navigation using machine intelligence may reduce post-surgical hospitalizations and lower costsDecember 04, 2020
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India December 04, 2020
PharmaEngine, Inc. collaborates with Sentinel Oncology for SOL-578, a Chk1 inhibitorDecember 04, 2020
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND ApplicationDecember 04, 2020
1450 new cases of COVID-19 reported in Madhya PradeshDecember 04, 2020
COVID-19 recovery rate in country improves to 94.20 pctDecember 04, 2020
Over 11,70,000 samples tested for COVID-19 across country in last 24 hoursDecember 04, 2020
Britain to cover COVID-19 vaccine side-effects under damages schemeDecember 04, 2020
India’s Active Caseload further dips to 4.35% of Total CasesDecember 04, 2020
COVID-19 recovery rate in Bihar improves to 97.12 pctDecember 04, 2020
Gujarat records 1540 new cases of COVID-19December 04, 2020
Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAADecember 04, 2020
AbbVie and Frontier Medicines establish global partnership for research and developmentDecember 04, 2020